NewsHK
Post-combination integration carries governance risks that do not always resolve quietly. In a current report submitted to the SEC and signed September 18, Glucotrack, Inc. (Nasdaq: GCTK) disclosed that director Paul V.
Goode resigned on September 14 with immediate effect, citing a potential conflict of interest between the company and a subsidiary arising from ongoing discussions over the implementation of the Lokahi Therapeutics merger agreement.
The 8-K, signed by Chief Executive Officer Erik Emerson, sets out Goode's stated reasoning directly: he concluded that a conflict exists between Glucotrack and its subsidiary in connection with discussions over how the parties should implement their respective duties, rights and obligations under the merger agreement by which the company completed its business combination with Lokahi Therapeutics, Inc.
The filing is silent on what specific provision of that agreement is at issue.
Keep reading